A curious team of explorers, deeply rooted in science, and constantly on the lookout for a very particular novel drug modality. This is us – Proxygen. We hunt for glue degraders. They are the key to unlocking new treatments for patients. They revolutionize how we see and cure diseases.
| Website | https://proxygen.com |
| Revenue | $5.1 million |
| Employees | 36 (31 on RocketReach) |
| Industry | Biotechnology Research |
| Keywords | Drug Discovery, Drug Development, Pharmaceutical Research, Biomedical Research, Biotechnology, Protein Degradation, Scientific Research, Pharmaceutical Science, Therapeutic Innovation, Biopharma, Therapeutic Development, Exploratory Research, Molecular Biology, New Treatments, Life Sciences, Clinical Development, Patient Care, Healthcare Innovation |
| Competitors | Amazon, Microsoft, IBM, Google, Okta, Ping Identity, Auth0 by Okta, Duo Security, OneLogin by One Identity +30 more (view full list) |
Looking for a particular Proxygen employee's phone or email?
The Proxygen annual revenue was $5.1 million in 2026.
Bernd Boidol is the CEO of Proxygen.
31 people are employed at Proxygen.